ArticleCell2025
Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias.
Abstract read
In one paragraph
Article in Cell, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed.
- Article
- Immune and cellular determinants of response to HMA-venetoclax regimens in acute myeloid leukemia.HemaSphere · 2026Article
- Minor histocompatibility antigen TCR-T.Blood advances · 2026Review
- Splicing-mediated control of hnRNPD isoform switching by SRSF2 drives PD-L1-dependent immune evasion in gallbladder cancer.Oncogene · 2026Article
- Review
- TargetingGenes & development · 2026Article
- Review
- Nonsense-Mediated RNA Decay Is a Targetable Vulnerability in Splicing Factor Mutant Myeloid Neoplasms by Enhancing R-Loop Accumulation and DNA Damage.Cancer research · 2026Article
- Splicing-driven post-translational dysregulation: a new frontier for precision cancer medicine and immunotherapy.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Outstanding Questions to Understand and Target Splicing Factor-Mutant Blood Cancers.Blood cancer discovery · 2026Article
- Novel and emerging therapeutic strategies for clonal hematopoiesis.Haematologica · 2026Review
- Spirocyclic β-lactone secondary metabolites modulate spliceosome function.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- A Yeast-Based High-Throughput Screening Platform for the Discovery of Novel pre-mRNA Splicing Modulators.ACS chemical biology · 2026Article
- Pharmacological perturbation of splicing elicits SMG1 reduction: Implications for cancer therapy.iScience · 2026Article
- Pipe dream to pipeline: Journey of cancer vaccines and the road ahead.Cell reports. Medicine · 2026Review
- mRNA vaccines in cancer immunotherapy: current progress and perspectives in solid tumors and hematologic malignancies.MedScience · 2026Review
- CHIP ahoy: charting a decade of discovery in clonal hematopoiesis.Haematologica · 2026Review
- Alternative splicing in cancer drug resistance: Mechanisms and therapeutic prospects (Review).Oncology reports · 2026Review
- Article
- Targeting splicing-derived neoantigens for precision cancer immunotherapy.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
36 authors.
Won Jun KimMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Edie I CrossePublic Health Sciences and Basic Sciences Divisions, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Emma De NeefPublic Health Sciences and Basic Sciences Divisions, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Genome Sciences, University of Washington, Seattle, WA, USA.
Inaki EtxeberriaHuman Oncology and Pathogenesis Program, MSK, New York, NY, USA.
Erich Y SabioMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Eric WangThe Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
Jan Philipp BewersdorfMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Kuan-Ting LinCodify Therapeutics, Cambridge, MA, USA.
Sydney X LuDepartment of Medicine, Division of Hematology, Stanford University, Palo Alto, CA, USA.
Andrea BellevillePublic Health Sciences and Basic Sciences Divisions, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Nina FoxMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Cynthia CastroMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Pu ZhangMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Takeshi FujinoMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Jennifer LewisMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Jahan RahmanMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Beatrice ZhangMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Jacob H WinickMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Alexander M LewisMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Robert F StanleyMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Susan DeWolfMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Brigita Meškauskaitė UrbenSingle-cell Analytics Innovation Laboratory, MSK, New York, NY, USA.
Meril TakizawaSingle-cell Analytics Innovation Laboratory, MSK, New York, NY, USA.
Tobias KrauseSingle-cell Analytics Innovation Laboratory, MSK, New York, NY, USA.
Henrik MolinaProteomics Resource Center, Rockefeller University, New York, NY, USA.
Ronan ChaligneSingle-cell Analytics Innovation Laboratory, MSK, New York, NY, USA.
Priya KoppikarDepartment of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jeffrey MolldremDepartment of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Mathieu GigouxSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Sandra and Edward Meyer Cancer Center, Weill Cornell Medical Center, New York, NY, USA.
Taha MerghoubSwim Across America and Ludwig Collaborative Laboratory, Department of Pharmacology, Sandra and Edward Meyer Cancer Center, Weill Cornell Medical Center, New York, NY, USA.
Anthony DaniyanMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA.
Smita S ChandranHuman Oncology and Pathogenesis Program, MSK, New York, NY, USA.
Benjamin D GreenbaumComputational Oncology, Department of Epidemiology and Biostatistics, MSK, New York, NY, USA.
Christopher A KlebanoffHuman Oncology and Pathogenesis Program, MSK, New York, NY, USA; Parker Institute for Cancer Immunotherapy, New York, NY, USA. Electronic address: klebanoc@mskcc.org.
Robert K BradleyPublic Health Sciences and Basic Sciences Divisions, Fred Hutchinson Cancer Center, Seattle, WA, USA; Department of Genome Sciences, University of Washington, Seattle, WA, USA. Electronic address: rbradley@fredhutch.org.
Omar Abdel-WahabMolecular Pharmacology Program, Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center (MSK), New York, NY, USA. Electronic address: abdelwao@mskcc.org.
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4MTargeting Oncogenic Pathways in Genetically Complex SarcomasP50CA217694 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Marc Ladanyi · 2018 to 2026
$21.5MThe Memorial Sloan Kettering Cancer Center SPORE in LeukemiaP50CA254838 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Anthony Folawuyi Daniyan · 2021 to 2026
$16.8MGenetic and molecular basis for SRSF2 mutations in myelodysplasiaR01HL128239 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Omar Abdel-Wahab, Robert K Bradley · 2015 to 2026
$8.0MWeill Cornell/Rockefeller/Sloan Kettering MST ProgramT32GM152349 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI KATHARINE C HSU · 2024 to 2026
$6.6MFunctional and molecular consequences of SF3B1 mutations in human hematopoietic stem cellsR01HL151651 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Robert K Bradley, Sergei Doulatov · 2020 to 2026
$4.0MTri-Institutional PhD Program in Computational Biology & MedicineT32GM132083 · NIGMS · WEILL MEDICAL COLL OF CORNELL UNIV · PI Doron Betel, Iman Hajirasouliha · 2020 to 2026
$3.6MInterrogating the minor spliceosome to understand and treat leukemiaR01CA251138 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, BRADLEY, ROBERT K · 2020 to 2024
$3.3MMolecular mechanisms of T cell responses to a clonal neoantigen resulting from a mutated driver oncogene.R37CA259177 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Christopher Austin Klebanoff · 2021 to 2026
$3.1MSynthetic introns for selective targeting of RNA splicing factor-mutant leukemiaR01CA283364 · NCI · FRED HUTCHINSON CANCER CENTER · PI Omar Abdel-Wahab, Robert K Bradley · 2023 to 2026
$2.9MTargeting an RNA Binding Protein Network in Acute Myeloid LeukemiaR01CA242020 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI ABDEL-WAHAB, OMAR, AIFANTIS, IANNIS · 2020 to 2024
$2.7MTOX-driven CD8 T cell differentiation and dysfunction in tumorsR01CA269733 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Andrea Schietinger · 2023 to 2026
$2.4MNCI NIH HHS K08 CA293271NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA217694NCI NIH HHS P50 CA254838NCI NIH HHS R01 CA242020NCI NIH HHS R01 CA251138NCI NIH HHS R01 CA269733NCI NIH HHS R01 CA283364NCI NIH HHS R01 CA286507NCI NIH HHS R35 CA304457NCI NIH HHS R37 CA259177NHLBI NIH HHS F30 HL172602NHLBI NIH HHS R01 HL128239NHLBI NIH HHS R01 HL151651NIGMS NIH HHS T32 GM132083NIGMS NIH HHS T32 GM152349NIH HHS S10 OD028685
Abstract
Mutations in RNA splicing factors are prevalent across cancers and generate recurrently mis-spliced mRNA isoforms. Here, we identified a series of bona fide neoantigens translated from highly stereotyped splicing alterations promoted by neomorphic, leukemia-associated somatic splicing machinery mutations. We utilized feature-barcoded peptide-major histocompatibility complex (MHC) dextramers to isolate neoantigen-reactive T cell receptors (TCRs) from healthy donors, patients with active myeloid malignancy, and following curative allogeneic stem cell transplant. Neoantigen-reactive CD8
Indexed as
Antigens, NeoplasmLeukemiaReceptors, Antigen, T-CellRNA SplicingRNA Splicing FactorsCD8-Positive T-LymphocytesHumansMutationSerine-Arginine Splicing FactorsAntigens, NeoplasmReceptors, Antigen, T-CellRNA Splicing FactorsSerine-Arginine Splicing FactorsSRSF2 protein, humanacute myeloid leukemiaimmunotherapymyelodysplastic syndromesneoantigenRNA splicingSF3B1SRSF2T cell receptorU2AF1ZRSR2
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.